Adial Pharmaceuticals Net Income Applicable To Common Shares Over Time
| ADIL Stock | USD 1.01 0.01 0.98% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adial Pharmaceuticals Performance and Adial Pharmaceuticals Correlation. Adial |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Adial Pharmaceuticals and related stocks such as Transcode Therapeutics, Aditxt Inc, and Reviva Pharmaceuticals Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (15.8 M) | (15 M) |
| ADTX | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (851.9 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (24.9 M) | (26.1 M) |
| RVPH | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (846.8 K) | (3.8 M) | (8.5 M) | (24.3 M) | (21.9 M) | (20.8 M) |
| ATXI | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (3.2 M) | (12.3 M) | (21.5 M) | (25.9 M) | (5.2 M) | (3.7 M) | (3.7 M) | (3.4 M) | (3.5 M) |
| ALRN | (16.1 M) | (16.1 M) | (16.1 M) | (16.1 M) | (16.1 M) | (12.9 M) | (18.2 M) | (22.6 M) | (31.5 M) | (29.4 M) | (21.2 M) | (26.2 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| BPTH | (2.4 M) | (2.4 M) | (2.6 M) | (3.3 M) | (4.5 M) | (5.5 M) | (6.8 M) | (8.1 M) | (8.6 M) | (8.6 M) | (10.9 M) | (10.4 M) | (10.4 M) | (9.4 M) | (9.9 M) |
| BNTC | (7 M) | (7 M) | (7 M) | (7 M) | (11.5 M) | (24.8 M) | (5.7 M) | (11.6 M) | 2.6 M | (8.3 M) | (13.9 M) | (18.2 M) | (19.6 M) | (17.6 M) | (18.5 M) |
| HOTH | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (2.5 M) | (7.7 M) | (7.2 M) | (14.3 M) | (14.3 M) | (12.9 M) | (12.2 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | 31.7 M | (3.8 M) | (2.1 M) | (2.1 M) | (1.9 M) | (1.8 M) |
| NRBO | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (15 M) | (60 K) | (15.5 M) | (21.3 M) | (29.7 M) | (15.3 M) | (15.3 M) | (13.8 M) | (14.4 M) |
| VRAX | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (710.4 K) | (651 K) | (1.7 M) | (5.5 M) | (4.9 M) | (4.7 M) |
| RNXT | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (6.3 M) | (9.9 M) | (8.9 M) | (9.3 M) |
| KTTA | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (61.5 K) | (2.2 M) | (2.2 M) | (2 M) | (1.9 M) |
| TNXP | (3.5 M) | (3.5 M) | (9.4 M) | (10.9 M) | (27.6 M) | (48.1 M) | (38.8 M) | (21.1 M) | (29.4 M) | (31.1 M) | (52.2 M) | (92.3 M) | (116.9 M) | (105.2 M) | (99.9 M) |
Adial Pharmaceuticals and related stocks such as Transcode Therapeutics, Aditxt Inc, and Reviva Pharmaceuticals Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Adial Pharmaceuticals | ADIL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Virginia; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.01
Check out Adial Pharmaceuticals Performance and Adial Pharmaceuticals Correlation. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Adial Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.